Bio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference
Bio-Techne Corporation (NASDAQ: TECH) announced that Chuck Kummeth, CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. EST. Access the live webcast on Bio-Techne's Investor Relations website. The company specializes in high-quality purified proteins and reagent solutions, generating approximately $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne plays a vital role in research and diagnostics, offering products in protein analysis, genomic tools, and diagnostics.
- None.
- None.
MINNEAPOLIS, Dec. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Senior Director, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301196420.html
SOURCE Bio-Techne Corporation
FAQ
When will Bio-Techne present at the J.P. Morgan Healthcare Conference?
How can I access the Bio-Techne conference presentation?
What is Bio-Techne's stock symbol?
What were Bio-Techne's net sales for fiscal 2020?
What products does Bio-Techne offer?
